The FDA’s Center for Biologics Evaluation and Research (CBER) is entering a transitional phase as Vinay Prasad steps aside and Katherine Szarama takes over as acting director. The change follows Prasad’s turbulent tenure that included high-profile rare disease gene therapy disputes. Makary indicated a permanent director is expected to be announced within weeks, but Szarama’s interim role immediately affects how sponsors may interpret agency posture on biologics, including vaccines, gene therapies, and complex biologics where CMC and evidence standards are tightly scrutinized. Today’s update matters to the biotech community because CBER decisions can influence trial design requirements, endpoint acceptability, and the timing of regulatory submissions for therapies that rely on evolving evidentiary frameworks. The shift is likely to keep attention on rare disease pathways and biologics governance as industry waits for the permanent appointment.